More biosimilars are hitting the US market, but marketplace dynamics have made it difficult to take advantage of these therapies.
A panel of leading experts on oncology practice and payment discussed how biosimilar rebates shape payer policies and provider options during a webinar from MJH Life Sciences™, the parent company of The American Journal of Managed Care® (AJMC®).
The discussion was held on Monday, July 20, 2020, and moderated by Jeff Prescott, PharmD, senior vice president of Clinical Communications for MJH Life Sciences™. The panelists were Kathy Oubre, MS, chief operating officer of the Pontchartrain Cancer Center in Louisiana; Timothy Chiu, PharmD, BCPS, pharmacist evidence analyst and strategist for Kaiser Permanente; and Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA, clinical coordinator of Hematology/Oncology for The University of Arizona Cancer Center in Tucson.
Although more biosimilars are launching in the US market, numerous factors affect whether they actually become available in the clinic. The expectation has been that as more biosimilars are approved and launch, costs will decline and providers will have more freedom to choose the appropriate medications for their patients. However, providers who want to use biosimilars find their choices are often determined by regional payer-by-payer contracts that require careful pharmacy planning, staff training, and sometimes, compromise.
To learn more about biosimilars, visit AJMC®'s sister site, The Center for Biosimilars™.
Use of AI Lets Health System Find Lung Cancer at Early Stages
March 8th 2025Artificial intelligence (AI) helps a Sarasota, Florida, health system catch lung nodules that appear on CT scans for patients treated for scores of conditions, allowing them to be referred for a possible lung cancer diagnosis.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Demographic Disparities in Video Visit Telemetry: Understanding Telemedicine Utilization
March 7th 2025A stratified demographics analysis of video visit telemetry data reveals that age older than 65 years and African American/Black race are associated with higher video visit failure rates, whereas language, sex, and ethnicity are not.
Read More
Facilitators of and Barriers to Medicaid Investment in Electronic Consultation Services
March 5th 2025In this qualitative investigation, leaders of Medicaid managed care plans were interviewed to identify facilitators of and barriers to electronic consultation for specialty care delivery.
Read More
More than 5 years after the American Society of Clinical Oncology warned of emerging disparities in precision medicine, efforts by community practices to embrace technology, form partnerships, and use data show how patients can gain access to personalized approaches. But challenges remain, especially for those covered by Medicaid.
Read More